RSS

Category Archives: etanercept

Rapid Improvement Etanercept in Action

I finally found a website that has a great demonstration of Etanercept in action. The site is called Medscape. It does require a registration. However, the process is easy and it is free.

The page you will be visiting is easy to view and the videos are short and clear. The page also contains the Case Study. The case study is very interesting. Linked pages contain detailed scientific information if that is of interest to you.

Go take a look if you have the time.

Patient with primary progressive aphasia before and 30 minutes after receiving perispinal etanercept

Please consider signing up for our email list or RSS feed. The buttons are in the upper right hand corner of this page.

This is the highest quality presentation I have seen on Etanercept. To make it simple to view I am including the links to Medscape Today. If you click the Video 1 or Video 2 link you can get directly to the video that shows Etanercept in action.

Perispinal Etanercept Produces Rapid Improvement in Primary Progressive Aphasia: Identification of a Novel, Rapidly Reversible TNF-Mediated Pathophysiologic Mechanism

You may need to register for the site to get in. However, the registration is free and easy. The quality of the presentation is well worth the effort.

If you would prefer to skip the highly technical part of the research you can go directly to the Case Study Page. On this page you can view two high quality video presentations.

Video 1. Patient with primary progressive aphasia before and 30 minutes after receiving perispinal etanercept.

Video 2. 1-month follow-up with patient and her daughter, following the patient’s third dose of perispinal etanercept.

Amazon.com Widgets

Advertisements
 

Does Etanercept (Enbrel) Work on Alzheimer’s Patients?

A study reported in the journal BioMed Central BMC Neurology showed that 12 patients improved language recall shortly after treatment with Enbrel, or etanercept, a rheumatoid arthritis drug. The study conducted by Dr. Edward Tobinick, director of the Institute for Neurological Research, was conducted in house without any of the controls usually seen in clinical trials.

The study is limited because people knew they were getting the drug and the result could be explained by the “placebo” effect. It is not unusual for Alzheimer’s patients to show improvement in open-label studies.

One has to wonder about Dr. Tobinck’s real motives since he charges $10,000-$40,000 per treatment. An outrageous price in my opinion. He does hold several patents on a special method of injecting the drug into the neck.

Hopefully we will see independent studies by scientist without financial interest to determine if this treatment should move forward and if it really works.

It should be noted that this unapproved treatment is not supported nor endorsed by Amgen. You can read the reaction they posted on the Amgen website here.

If you want to view a video of the results on patients after the etanercept injection follow this link…Video

Other articles on this topic:

Etanercept (Enbrel) in Action, see Alzheimer’s patient’s memory come alive (Video)

Video Released Of Rapid Alzheimer’s Improvement After New Immune-based Treatment

BioMed Central

Reversing Symptoms of Alzheimer’s?

 
 

‘Instant’ Alzheimer’s Drug Claim, Enbrel (Etanercept)


Ten minutes after the injection, the researchers reported that the patient was calmer, less frustrated and more attentive. He could correctly identify California as his home state, but incorrectly identified the current year. At two hours, the Montreal Cognitive Assessment had improved from seven out of a possible 30 to 15. The man’s wife and son confirmed the improvements.

‘Instant’ Alzheimer’s Drug Claim

A drug used for arthritis can reverse the symptoms of Alzheimer’s ‘in minutes'”, the Daily Mail reported. Several newspapers covered the story of how an 81-year-old man with Alzheimer’s disease improved within 10 minutes of being injected with a new drug, etanercept. The BBC reported that his wife described the effect on her husband as being “put back to where he was”. His son said, “This was the single most remarkable thing I’ve seen”.

Reports of success in single patients often herald the start of a new line of investigation into diseases and drugs. Though anecdotal evidence holds promise for patients, families and researchers, most of the news reports suggest that it is too soon to say if this drug will fulfil its potential. Larger, placebo controlled studies will be required to determine if this drug is safe or effective for this disease. The drug has the advantage that it has already been approved as safe for use in humans for treating arthritis, and this could speed up the process of testing its effectiveness in treating Alzheimer’s.

Where did the story come from?

Dr Edward Tobnick from the Institute of Neurological Research and Dr Hyman Gross from the USC School of Medicine in Los Angeles carried out this research. The institute is a private medical group and there was no funding from outside sources. Competing interests were declared.

The study was published online in the Journal of Neuroinflammation.

What kind of scientific study was this?

This was a case study (a study in one person) that tested the short-term effects of the drug etanercept on a patient with Alzheimer’s disease.

The researchers first obtained the written consent of the patient and his wife and explained the potential risks of the drug, which included infection and death. They then conducted a routine examination of the 81-year-old retired doctor followed by a range of tests for memory, attention and mathematical ability. The Montreal Cognitive Assessment (which assesses mild cognitive dysfunction) was used to give a numerical score for the degree of dementia. Prior to the injection the score was seven out of a possible 30 points, a number consistent with moderate to severe dementia.

The drug was then injected around the spinal cord at neck level, and the patient was placed with his head downwards, so that the drug would run to the head. The patient was re-examined after a 10 minute and two hour interval.

The drug etanercept belongs to a class of drugs called TNF-alpha blockers. These are increasingly used for the treatment of severe rheumatoid arthritis and other conditions caused by inflammation. This type of drug is usually administered by injection into muscle. It acts by deactivating a chemical involved in the early stages of generalised inflammation and in regulating immune cells – tumour necrosis factor (TNF). The researchers had already conducted a study that measured the drug’s longer-term effects in 15 patients over a six month period and this study was aimed at assessing the rapid effects of the drug.

What were the results of the study?

Ten minutes after the injection, the researchers reported that the patient was calmer, less frustrated and more attentive. He could correctly identify California as his home state, but incorrectly identified the current year. At two hours, the Montreal Cognitive Assessment had improved from seven out of a possible 30 to 15. The man’s wife and son confirmed the improvements.

What interpretations did the researchers draw from these results?

In their discussion of the results, the researchers describe the biological mechanisms providing the rationale for trying out this drug. They suggest it is a promising area for additional investigation and therapeutic intervention.

What does the NHS Knowledge Service make of this study?

As a case report of a single patient, this study represents very early evidence in the long journey from drug development to clinical use in patients. Disadvantages to this type of study include:

– the lack of any control patients against which the effect can be compared, meaning that it may be that some of the improvements, for example the lessened anxiety, could have occurred by sitting in the doctors office for long enough without being given any medication
– the lack of long term follow up means that it is not possible to know how long any suggested improvement may last
– the lack of results from other patients mean the effect may not be seen in other people

The drug has an advantage in that it is already approved for use in other conditions and therefore something is already known of its safety. The long and short term effects of drugs can be markedly different and this study may stimulate further research into the short term effects of etanercept for dementia.

While providing hope for those who suffer from Alzheimer’s and their families, this case study should be regarded as a preliminary finding of this drug’s use as a treatment for the disease. Further controlled studies of the drug’s effects in a larger group of people would be required to test the drug’s effectiveness properly.

Links to the science

Tobinick EL, Gross H. Rapid cognitive improvement in Alzheimer’s disease following perispinal etanercept administration.J Neuroinflammation 2008; 5:2

This news comes from the National Health Service (NHS) of the UK.
http://www.nhs.uk/News/Pages/NewsIndex.aspx

Article URL: http://www.medicalnewstoday.com/articles/94072.php

Main News Category: Alzheimer’s / Dementia

 

Reversing Symptoms of Alzheimer’s?

Might be a breakthrough. We can only hope.

clipped from www.foxnews.com

A patient with Alzheimer’s disease had their condition improve hugely just minutes after receiving a special injection of a prescription drug approved to treat psoriasis and rheumatoid arthritis and other conditions, according to a new study.

The drug, co-marketed in the U.S. by Amgen and Wyeth under the name Enbrel, dramatically reversed symptoms of an Alzheimer’s disease sufferer minutes after it was injected into the patient’s spine, researchers in the U.S. discovered. The drug, sold in Australia as Etanercept, has also been used off-label for treating Alzheimer’s.

an “exciting” breakthrough, which provided a greater understanding of the disease. “It is unprecedented that we can see cognitive and behavioral improvement in a patient with established dementia within minutes of therapeutic intervention,” Griffin said.

this report details rapid cognitive improvement, beginning within minutes, using this same… treatment modality, in a patient with late-onset Alzheimer’s disease.”

blog it

Arthritis Drug Shows Promise in Reversing Symptoms of Alzheimer’s

A patient with Alzheimer’s disease had their condition improve hugely just minutes after receiving a special injection of a prescription drug approved to treat psoriasis and rheumatoid arthritis and other conditions, according to a new study.

The drug, co-marketed in the U.S. by Amgen and Wyeth under the name Enbrel, dramatically reversed symptoms of an Alzheimer’s disease sufferer minutes after it was injected into the patient’s spine, researchers in the U.S. discovered. The drug, sold in Australia as Etanercept, has also been used off-label for treating Alzheimer’s.

A report on the new study appeared in the Journal of Neuroinflammation this week.

Click here for the full study

Journal editor Professor Sue Griffin from the University of Arkansas said the study was an “exciting” breakthrough, which provided a greater understanding of the disease. “It is unprecedented that we can see cognitive and behavioral improvement in a patient with established dementia within minutes of therapeutic intervention,” Griffin said.

“This gives all of us in Alzheimer’s research a tremendous new clue about new avenues of research, which is so exciting and so needed in the field of Alzheimer’s.

“Even though this report predominantly discusses a single patient, it is of significant scientific interest because of the potential insight it may give into the processes involved in the brain dysfunction of Alzheimer’s.”

Professor Edward Tobinick from the University of California and Professor Hyman Gross from the University of Southern California made the discovery while treating a patient who developed Alzheimer’s disease later in life.

“The efficacy of (Enbrel) … delivered by perispinal administration, for treatment of Alzheimer’s disease over a period of six months has been previously reported in a pilot study,” the researchers said.

“(But) this report details rapid cognitive improvement, beginning within minutes, using this same… treatment modality, in a patient with late-onset Alzheimer’s disease.”

 
 
%d bloggers like this: